In April 2017, we received FDA clearance for the acute treatment of pain associated with episodic cluster headache. We began commercial distribution in the US shortly after.
In April 2017, we received FDA clearance for the acute treatment of pain associated with episodic cluster headache. We began commercial distribution in the US shortly after.